Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions
This is a clinical trial to evaluate the intravenous administration of indocyanine green (ICG) as a method of intra-thoracic lesion localization. The primary purpose is to determine if intravenous ICG allows us to identify intra-thoracic lesions.
Checked against the public recordLast updated Dec 12, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Device Feasibility
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Brigham and Women's Hospital
- Interventions being studied
- Drug: ICG Intervention; Device: Near Infrared Camera
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients with intra-thoracic lesions that require resection for therapeutic or diagnostic purposes as recommended by their thoracic surgeon. * 18 years of age or older * Documented, signed, dated informed consent obtained prior to any study specific procedures being performed Exclusion Criteria: * Subjects who do not wish to have subsequent surgical resection * A medical condition such as uncontrolled infection or cardiac disease that, in the opinion of the treating surgeon, makes resection unreasonably hazardous for the patient * Pre-operative spirometry that suggests the patient is at high risk or cannot undergo resection of the primary tumor. * Iodide or seafood allergy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Brigham and Women's HospitalBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 12, 2017. Always confirm current availability with the study team.